How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chemotherapy-induced-nausea-and-vomiting.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chemotherapy-induced nausea and vomiting — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chemotherapy-induced nausea and vomiting (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chemotherapy-induced nausea and vomiting, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Akynzeo	FOSNETUPITANT	Helsinn Hlthcare	Serotonin-3 Receptor Antagonist [EPC]	Substance-P receptor	2018-01-01
Varubi	ROLAPITANT	Tersera	Substance P/Neurokinin-1 Receptor Antagonist	Substance-P receptor	2015-01-01
Akynzeo	NETUPITANT	Helsinn Hlthcare	Serotonin-3 Receptor Antagonist [EPC]	Substance-P receptor	2014-01-01
Emend	APREPITANT	Merck & Co.	Substance P/Neurokinin-1 Receptor Antagonist [EPC]	Substance-P receptor	2003-01-01
Zofran	ondansetron	GSK (originally Glaxo)	5-HT3 receptor antagonist (antiemetic)	Aldehyde oxidase, 5-hydroxytryptamine receptor 3B, Multidrug and toxin extrusion protein 1	1991-01-04
Marinol	DRONABINOL	Wellhouse Pharma	Cannabinoid [EPC]	Cannabinoid receptors	1985-01-01
Cesamet	NABILONE	Bausch Health	Cannabinoid [EPC]	Cannabinoid receptor 1	1985-01-01
Estron	ESTRONE	Watson Labs	estrone	Estrogen receptor	1979-01-01
Reglan	METOCLOPRAMIDE	Hikma	Dopamine-2 Receptor Antagonist	D(3) dopamine receptor	1979-01-01
Reglan	Metoclopramide Hydrochloride	Hikma	Prokinetic agent	Acetylcholine receptor sensitization; dopamine antagonism (implied)	1979-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Hikma · 2 drugs in Chemotherapy-induced nausea and vomiting
Helsinn Hlthcare · 2 drugs in Chemotherapy-induced nausea and vomiting
· 2 drugs in Chemotherapy-induced nausea and vomiting
GSK (originally Glaxo) · 1 drug in Chemotherapy-induced nausea and vomiting
Institute of Liver and Biliary Sciences, India · 1 drug in Chemotherapy-induced nausea and vomiting
Jazz Pharmaceuticals · 1 drug in Chemotherapy-induced nausea and vomiting
Merck & Co. · 1 drug in Chemotherapy-induced nausea and vomiting
Tersera · 1 drug in Chemotherapy-induced nausea and vomiting
Veeda Oncology · 1 drug in Chemotherapy-induced nausea and vomiting
Wageningen University · 1 drug in Chemotherapy-induced nausea and vomiting
Watson Labs · 1 drug in Chemotherapy-induced nausea and vomiting
Wellhouse Pharma · 1 drug in Chemotherapy-induced nausea and vomiting

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chemotherapy-induced nausea and vomiting:

Cite this brief

Drug Landscape (2026). Chemotherapy-induced nausea and vomiting — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chemotherapy-induced-nausea-and-vomiting. Accessed 2026-06-10.

Chemotherapy-induced nausea and vomiting full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing